PREDILIFE (EPA:ALPRE) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Home
Companies
PREDILIFE

BRIEF

published on 11/07/2024 at 18:35, 13 days 15 hours ago

Subsidiary of MammoRisk by Predilife for €202 million

MammoRisk Breast Cancer International Development Subsidiary Valorization
BRIEF

published on 10/30/2024 at 19:05, 21 days 15 hours ago

Predilife publishes its 2024 half-yearly financial report

Artificial Intelligence Financial Report Euronext Growth PREDILIFE Medical Prediction
BRIEF

published on 10/28/2024 at 08:35, 24 days 1 hour ago

PREDILIFE Half-Yearly Results and Outlook for 2024

Financial Results Strategic Partnerships Growth 2024 PREDILIFE MammoRisk®
BRIEF

published on 10/21/2024 at 18:35, 30 days 15 hours ago

The Rocher Group is committed to women's health with PREDILIFE

PREDILIFE Breast Cancer Pink October Rocher Group Health Prevention
BRIEF

published on 10/08/2024 at 08:50, 1 month 13 days ago

Predilife reaches the milestone of 1,000 registrations for its predictive assessments

PREDILIFE Pathologies MammoRisk Predictive Assessments Pink October
BRIEF

published on 10/02/2024 at 20:35, 1 month 18 days ago

Signing of the Mammorisk partial asset contribution agreement by Predilife

PREDILIFE MammoRisk Breast Cancer Subsidiary Personalized Screening
BRIEF

published on 07/19/2024 at 18:05, 4 months 1 day ago

Half-year review of the PREDILIFE liquidity contract as of June 30, 2024

Liquidity Transactions Half-yearly PREDILIFE FASD
BRIEF

published on 07/12/2024 at 19:20, 4 months 8 days ago

PREDILIFE raises funds of €775,000

Fundraising Convertible Bonds Treasury Funding PREDILIFE
BRIEF

published on 05/29/2024 at 18:35, 5 months 22 days ago

PREDILIFE STRENGTHENS ITS ASSETS WITH A NEW AI PATENT

Artificial Intelligence Patent PREDILIFE MammoRisk MyPeBS
PRESS RELEASE

published on 05/29/2024 at 18:30, 5 months 22 days ago

PREDILIFE STRENGTHENS ITS ASSETS WITH THE ISSUANCE OF A PATENT FOR ITS AI METHOD
PREDILIFE obtains European patent for its AI breast cancer risk prediction method, reinforcing its assets. The method's strong performance and diverse applications position it as a valuable asset in the field of predictive medicine

PREDILIFE Breast Cancer Predictive Medicine European Patent AI Method

Accesswire

Published on 11/21/2024 at 10:03, 28 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 31 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 31 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 56 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 6 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 26 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 28 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 30 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 30 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 29 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 33 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 11 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 46 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 46 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE